| Literature DB >> 31583047 |
Zhebo Liu1,2,3, Bo Tao1,2,3, Suzhen Fan1,2,3, Yong Pu4, Hao Xia1,2,3, Lin Xu1,2,3.
Abstract
MicroRNA-145 (miR-145) has been shown to play an important role in cardiovascular system disorders; however, the underlying mechanism is not completely understood. The purpose of this study was aimed at elucidating the cardioprotective effects of miR-145 against myocardial ischemia/reperfusion (I/R) injury. We established a rat myocardial I/R model with 45 min left anterior descending coronary artery (LAD) occlusion and 2 h reperfusion. The levels of myocardial enzymes, apoptotic, inflammatory, and oxidative indices were determined. The arrhythmia score was assessed by programmed electrical stimulation (PES). Quantitative real-time PCR and western blot were applied to evaluate the expression levels of miR-145 and related target proteins, respectively. I/R injury decreased the expression of miR-145; however, upregulated miR-145 markedly reduced the elevation of ST segment, decreased corrected QT (QTc) intervals, and attenuated I/R-induced electrophysiological instability. Furthermore, miR-145 suppressed myocardium apoptotic, inflammatory, and oxidative response as well as the phosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaMKII), ryanodine receptor2 (RyR2 Ser2814), apoptosis signal-regulating kinase 1 (ASK1), c-Jun NH2-terminal kinases (JNK), and nuclear translocation of nuclear factor kappa-B (NF-κB) p65. In summary, overexpression of miR-145 alleviates I/R-induced myocardial electrophysiological instability and apoptotic and inflammatory response via inhibition of the CaMKII-mediated ASK1 antiapoptotic pathway and NF-κB p65 anti-inflammatory pathways.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31583047 PMCID: PMC6754948 DOI: 10.1155/2019/8948657
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Score criterion of PES.
| Score | Score criterion |
|---|---|
| 0 | Noninducible preparations |
| 1 | Nonsustained tachyarrhythmias induced with three extrastimuli |
| 2 | Sustained tachyarrhythmias induced with three extrastimuli |
| 3 | Nonsustained tachyarrhythmias induced with two extrastimuli |
| 4 | Sustained tachyarrhythmias induced with two extrastimuli |
| 5 | Nonsustained tachyarrhythmias induced with one extrastimulus |
| 6 | Sustained tachyarrhythmias induced with one extrastimulus |
| 7 | Tachyarrhythmias induced during the eight paced beats |
| 8 | Cardiac arrest without pacing |
Figure 1miR-145 attenuated myocardial I/R injury. (a) Relative expression of miR-145 (n = 4). (b) The expression of LDH (n = 6). (c) The expression of CK-MB (n = 6). (d) The contents of MDA (n = 6). (e) The activities of SOD (n = 6). (f) Damage score (n = 6). (g) Representative images of H&E-stained samples (200x magnification).
Figure 2miR-145 suppressed the myocardial I/R injury and susceptibility to VT in an I/R-injured myocardium. (a) Typical segments of ECG on basic; ischemia for 30 min; and reperfusion for 30 min, 60 min, and 120 min. (b) The elevation of ST segment (n = 6). (c) The changes of QTc interval (n = 6). (d) Examples of PES recordings. (e) Arrhythmia score during ischemia period (n = 6). (f) Arrhythmia score during reperfusion period (n = 6). I: ischemia; R: reperfusion; VT: ventricular tachyarrhythmias; ∗P < 0.05 compared with the sham group; #P < 0.05 compared with the I/R group; &P < 0.05 compared with the AD-Scramble group.
Figure 3miR-145 upregulation suppressed myocardial apoptosis. (a) Representative images of TUNEL assays (200x magnification). (b) Apoptosis index (n = 6). (c) Representative western blots of Bcl-2 and Bax. (d–f) Quantitative analysis of the immunoreactive band displayed by a bar graph (n = 3). (g) Representative western blots of cleaved caspase 3 and caspase 3. (H) Quantitative analysis of the immunoreactive band displayed by a bar graph (n = 3). (a) Sham group, (b) I/R group, (c) AD-Scramble group, (d) AD-miR-145 group, the (e) IPC group.
Figure 4Representative images of echocardiograph.
Effects of miR-145 on cardiac function.
| Sham | I/R | AD-Scramble | AD-miR-145 | IPC | |
|---|---|---|---|---|---|
| HR (beats/min) | 438.25 ± 12.31 | 430.00 ± 10.29 | 428.25 ± 11.58 | 423.25 ± 8.77 | 428.25 ± 11.06 |
| LVEDd (mm) | 5.07 ± 0.15 | 5.13 ± 0.17 | 5.15 ± 0.17 | 5.01 ± 0.18 | 5.03 ± 0.13 |
| LVEDs (mm) | 2.20 ± 0.22 | 3.30 ± 0.22∗ | 3.27 ± 0.13 | 3.05 ± 0.13 | 3.07 ± 0.11 |
| FS (%) | 61.37 ± 1.78 | 34.33 ± 1.29∗ | 35.34 ± 2.09 | 38.44 ± 1.59#,& | 40.28 ± 2.92# |
HR: heart rate; LVEDd: left ventricular end-diastolic dimension; LVEDs: left ventricular end-systolic dimension; FS: fractional shortening. ∗P < 0.05, compared with the sham group; #P < 0.05, compared with the I/R group; &P < 0.05, compared with the AD-Scramble group.
Figure 5Mechanism underlying cardioprotective effects of miR-145. (a) Representative western blots. (b–g) Quantitative analysis of the immunoreactive band displayed by a bar graph (n = 3). (A) Sham group, (B) I/R group, (C) AD-Scramble group, (D) AD-miR-145 group, and (E) IPC group.
Figure 6miR-145 inhibited inflammatory response against I/R injury. (a) Representative immunofluorescence images (400x magnification). (b) Representative western blots. (c–g) Quantitative analysis of the immunoreactive band displayed by a bar graph (n = 3). (a) Sham group, (b) I/R group, (c) AD-Scramble group, (d) AD-miR-145 group, and (e) IPC group.